АУТОПЛАЗМА, ОБОГАЩЕННАЯ ТРОМБОЦИТАРНЫМИ ФАКТОРАМИ РОСТА, В ЛЕЧЕНИИ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ: ОБЗОР ДОКЛИНИЧЕСКИХ И КЛИНИЧЕСКИХ ИССЛЕДОВАНИЙ

Эректильная дисфункция (ЭД) давно перестала быть только психосоциальной проблемой. Сегодня это маркер сердечно-сосудистых заболеваний. Применение аутоплазмы, обогащенной тромбоцитарными факторами роста (АОТ), является новым и многообещающим методом, заслуживающим внимания специалистов. В обзоре представлены существующие на данный момент доклинические и клинические исследования, опубликованные в базах данных PubMed, Cochrane Library, Clinicaltrials.gov, по применению АОТ в лечении ЭД. Имеющиеся данные доклинических и клинических исследований говорят об эффективности использования данной методики для лечения ЭД и отсутствии побочных эффектов. АОТ является патогенетически обоснованным методом лечения ЭД, который направлен на репарацию и регенерацию эндотелия, гладкомышечных клеток и соединительной ткани. Однако для формирования систематического обзора и метаанализа необходимо проведение большего числа крупных плацебо-контролируемых многоцентровых исследований.

1. Colson MH, Cuzin B, Faix A, Grellet L, Huyghes E. Erectile dysfunction : up-date data and clinical guidelines. Rev Med Suisse. 2019 Mar 13;15 (642):583–589. [Article in French].

2. Shaeer O, Shaeer K. The Global Online Sexuality Survey (GOSS): the United States of America in 2011. Chapter I: erectile dysfunction among English-speakers. J Sex Med. 2012 Dec;9 (12):3018–27. DOI: 10.1111/j.1743–6109.2012.02976.x

3. Shaeer O, Shaeer K, Fode M, Serefoglu E. The Global Online Sexuality Survey (GOSS) 2015. Erectile Dysfunction Among English-Speaking Internet Users in the United States. Human Andrology. 2017;7 (4):111–9.

4. Пушкарь Д. Ю., Камалов А. А., Аль-Шукри С .Х., Еркович А.А., Коган М.И., Павлов В.Н., Журавлев В.Н., Берников А. Н. Анализ результатов эпидемиологического исследования распространенности эректильной дисфункции в Российской Федерации. Урология. 2012;6:5–9.

5. Çayan S, Kendirci M, Yaman Ö, Aşçı R, Orhan İ, Usta MF, et al. Prevalence of erectile dysfunction in men over 40 years of age in Turkey: Results from the Turkish Society of Andrology Male Sexual Health Study Group. Turk J Urol. 2017 Jun;43 (2):122–129. DOI: 10.5152/tud.2017.24886

6. Boston University School of Medicine and Sexual Medicine. Epidemiology of ED. Available at: http://www.bumc.bu.edu/sexualmedicine/physicianinformation/epidemiology-of-ed/

7. Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, et al. Erectile Dysfunction: AUA Guideline. J Urol. 2018 Sep;200 (3):633–641. DOI: 10.1016/j.juro.2018.05.004

8. EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978–94–92671–01–1.

9. Pastuszak AW. Current Diagnosis and Management of Erectile Dysfunction. Curr Sex Health Rep. 2014 Sep;6 (3):164–176. DOI: 10.1007/s11930–014–0023–9

10. Priviero FB, Toque HA, Nunes KP, Priolli DG, Teixeira CE, Webb RC. Impaired Corpus Cavernosum Relaxation Is Accompanied by Increased Oxidative Stress and Up-Regulation of the Rho-Kinase Pathway in Diabetic (Db/Db) Mice. PLoS One. 2016;11 (5): e0156030. Published 2016 May 26. DOI: 10.1371/journal. pone.0156030

11. Nehra A, Goldstein I, Pabby A, Nugent M, Huang YH, de las Morenas A, et al. Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure. J Urol. 1996 Oct; 156 (4):1320–9.

12. Moreland RB. Is there a role of hypoxemia in penile ®brosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impot Res. 1998 Jun;10 (2):113–20.

13. El-Sakka AI. Reversion of penile fibrosis: Current information and a new horizon. Arab Journal of Urology. 2011;9 (1):49–55. DOI: 10.1016/j.aju.2011.03.013

14. Castela Â, Soares R, Rocha F, Vendeira P, Virag R, Costa C. Erectile tissue molecular alterations with aging–differential activation of the p42/44 MAP Kinase pathway. Age. 2011;33 (2):119–130. DOI: 10.1007/s11357–010–9167–3

15. Lindau ST, Tang H, Gomero A, Vable A, Huang ES, Drum ML, et al. Sexuality among middle-aged and older adults with diagnosed and undiagnosed diabetes: a national, population-based study. Diabetes Care. 2010 Oct;33 (10):2202–10. DOI: 10.2337/dc10–0524

16. Guo W, Liao C, Zou Y, Li F, Li T, Zhou Q, et al. Erectile dysfunction and risk of clinical cardiovascular events: a meta-analysis of seven cohort studies. J Sex Med. 2010 Aug;7 (8):2805–16. DOI: 10.1111/j.1743–6109.2010.01792.x

17. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005 Dec 21;294 (23):2996–3002. DOI: 10.1001/jama.294.23.2996

18. Loprinzi PD and Nooe A. Erectile dysfunction and mortality in a national prospective cohort study. J Sex Med. 2015 Nov;12 (11):2130–3. DOI: 10.1111/jsm.13032

19. Чалый М.Е., Григ орян В.А., Епиф анова М.В., К рас-нов А.О. Эффективность интракавернозного введения аутоплазмы, обогащенной тромбоцитами, в лечении эректильной дисфункции. Урология. 2015;4:76–9.

20. Kim DH, Je YJ, Kim CD, Lee YH, Seo YJ, Lee JH, Lee Y. Can Platelet-rich Plasma Be Used for Skin Rejuvenation? Evaluation of Effects of Platelet-rich Plasma on Human Dermal Fibroblast. Ann Dermatol. 2011 Nov;23 (4):424–31. DOI: 10.5021/ad.2011.23.4.424

21. Lee JW, Kwon OH, Kim TK, Cho YK, Choi KY, Chung HY, et al. Platelet-Rich Plasma: Quantitative Assessment of Growth Factor Levels and Comparative Analysis of Activated and Inactivated Groups. Arch Plast Surg. 2013 Sep;40 (5):530–5. DOI: 10.5999/aps.2013.40.5.530.

22. Cameli N, Mariano M, Cordone I, Abril E, Masi S, Foddai ML. Autologous Pure Platelet-Rich Plasma Dermal Injections for Facial Skin Rejuvenation: Clinical, Instrumental, and Flow Cytometry Assessment. Dermatol Surg. 2017 Jun;43 (6):826–835. DOI: 10.1097/DSS.0000000000001083

23. Anitua E, Muruzabal F, de la Fuente M, Merayo J, Durán J, Orive G. Plasma Rich in Growth Factors for the Treatment of Ocular Surface Diseases. Curr Eye Res. 2016 Jul;41 (7):875–82. DOI: 10.3109/02713683.2015.1104362.

24. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-Rich Plasma From Basic Science to Clinical Applications. Am J Sports Med. 2009 Nov;37 (11):2259–72. DOI: 10.1177/0363546509349921

25. Daif ET. Effect of autologous platelet-rich plasma on bone regeneration in mandibular fractures. Dent Traumatol. 2013 Oct;29 (5):399–403. DOI: 10.1111/edt.12021.

26. Sadeghi-Ataabadi M, Mostafavi-Pour Z, Vojdani Z, Sani M, Latifi M, Talaei-Khozani T. Fabrication and characterization of platelet-rich plasma scaffolds for tissue engineering applications. Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:372–380. DOI: 10.1016/j.msec.2016.10.001

27. Anjayani S, Wirohadidjojo YW, Adam AM, Suwandi D, Seweng A, Amiruddin MD. Sensory improvement of leprosy peripheral neuropathy in patients treated with perineural injection of platelet-rich plasma. Int J Dermatol. 2014 Jan;53 (1):109–13. DOI: 10.1111/ijd.12162.

28. Teymur H, Tiſtikcioglu YO, Cavusoglu T, Tiſtikcioglu BI, Erbas O, Yigitturk G, Uyanikgil Y. Effect of platelet-rich plasma on reconstruction with nerve autograſts. Kaohsiung J Med Sci. 2017 Feb;33 (2):69–77. DOI: 10.1016/j.kjms.2016.11.005

29. Ahmed M, Reffat SA, Hassan A, Eskander F. Platelet Rich Plasma for the Treatment of Clean Diabetic Foot Ulcers. Ann Vasc Surg. 2017 Jan;38:206–211. DOI: 10.1016/j.avsg.2016.04.023

30. Patel AN, Selzman CH, Kumpati GS, McKellar SH, Bull DA. Evaluation of autologous platelet rich plasma for cardiac surgery: outcome analysis of 2000 patients. J Cardiothorac Surg. 2016 Apr 12;11 (1):62. DOI: 10.1186/s13019–016–0452–9

31. Taschieri S, Lolato A, Ofer M, Testori T, Francetti L, Del Fabbro M. Immediate post-extraction implants with or without pure platelet-rich plasma: a 5-year follow-up study. Oral Maxillofac Surg. 2017 Jun;21 (2):147–157. DOI: 10.1007/s10006–017–0609–2

32. Smith PA. Intra-articular autologous conditioned plasma injections provide safe and efficacious treatment for knee osteoarthritis An FDA-sanctioned, randomized, double-blind, placebo-controlled clinical trial. Am J Sports Med. 2016 Apr;44 (4):884–91. DOI: 10.1177/0363546515624678

33. Kumar CS. Combined Treatment of Injecting Platelet Rich Plasma With Vacuum Pump for Penile Enlargement. The Journal of Sexual Medicine. 2017;14 (1) :S78.

34. Banno JJ, Kinnick TR, Roy L, Perito P, Antonini G, Banno D. The Efficacy of Platelet-Rich Plasma (PRP) as a Supplemental Therapy for the Treatment of Erectile Dysfunction (ED): Initial Outcomes. The Journal of Sexual Medicine. 2017;14 (2 ):e59-e60.

35. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009 Mar;27 (3):158–67. DOI: 10.1016/j. tibtech.2008.11.009

36. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular Endothelial Growth Factor and Angiogenesis. Pharmacol Rev. 2004;56:549–580.

37. Raica M, Cimpean AM. Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy. Pharmaceuticals (Basel). 2010 Mar 11;3 (3):572–599. DOI: 10.3390/ph3030572

38. Murakami M, Simons M. Fibroblast growth factor regulation of neovascularization. Curr Opin Hematol. 2008 May;15 (3):215–20. DOI: 10.1097/MOH.0b013e3282f97d98

39. van Cruijsen H, Giaccone G, Hoekman K. Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. Int J Cancer. 2005 Dec 20;117 (6):883–8. DOI: 10.1002/ijc.21479

40. Jacobo SM, Kazlauskas A. Insulin-like Growth Factor 1 (IGF-1) Stabilizes Nascent Blood Vessels. J Biol Chem. 2015 Mar 6;290 (10):6349–60. DOI: 10.1074/jbc.M114.634154

41. Viñals F, Pouysségur J. Transforming Growth Factor β1 (TGF-β1) Promotes Endothelial Cell Survival during In Vitro Angiogenesis via an Autocrine Mechanism Implicating TGF-α Signaling. Mol Cell Biol. 2001 Nov;21 (21):7218–30. DOI: 10.1128/MCB.21.21.7218–7230.2001

42. Sclafani AP. Applications of platelet-rich fibrin matrix in facial plastic surgery. Facial Plast Surg. 2009 Nov;25 (4):270–6. DOI: 10.1055/s-0029–1242033

43. Middleton KK, Barro V, Muller B, Terada S, Fu FH. Evaluation of the effects of platelet-rich plasma (PRP) therapy involved in the healing of sports-related soſt tissue injuries. Iowa Orthop J. 2012;32:150–63.

44. Scarcia M, Maselli FP, Cardo G, Ludovico GM. The use of autologous platelet rich plasma gel in bulbar and penile buccal mucosa urethroplasty: Preliminary report of our first series. Arch Ital Urol Androl. 2016 Dec 30;88 (4):274–278. DOI: 10.4081/aiua.2016.4.274.

45. French WJ, Creemers EE, Tallquist MD. Platelet-derived growth factor receptors direct vascular development independent of vascular smooth muscle cell function. Mol Cell Biol. 2008 Sep;28 (18):5646–57. DOI: 10.1128/MCB.00441–08

46. Chen N-F, Sung C-S, Wen Z-H, Chen CH, Feng CW, Hung HC, et al. Therapeutic Effect of Platelet-Rich Plasma in Rat Spinal Cord Injuries. Front Neurosci. 2018 Apr 23;12:252. DOI: 10.3389/fnins.2018.00252

47. Zhang J, Middleton KK, Fu FH, Im H-J, Wang JH-C. HGF Mediates the Anti-inflammatory Effects of PRP on Injured Tendons. PLoS One. 2013 Jun 28;8 ( 6):e67303. DOI: 10.1371/journal. pone.0067303

48. Wu CC, Wu YN, Ho H.O., Chen KC, Sheu MT, Chiang HS. The neuroprotective effect of platelet-rich plasma on erectile function in bilateral cavernous nerve injury rat model. J Sex Med. 2012 Nov;9 (11):2838–48. DOI: 10.1111/j.1743–6109.2012.02881.x

49. Xie D, Pippen AM, Odronic SI, Annex BH, Donatucci CF. Intracavernosal basic fibroblast growth factor improves vasoreactivity in the hypercholesterolemic rabbit. J Sex Med. 2006 Mar;3 (2):223–32. DOI: 10.1111/j.1743–6109.2005.00174.x

50. Dai Q, Silverstein AD, Davies MG, Hagen PO, Donatucci CF, Annex BH. Systemic basic fibroblast growth factor induces favorable histological changes in the corpus cavernosum of hypercholesterolemic rabbits. J Urol. 2003 Aug;170 (2 Pt 1):664–8. DOI: 10.1097/01.ju.0000065247.55066.ad

51. Suetomi T, Hisasue S, Sato Y, Tabata Y, Akaza H, Tsukamoto T. Effect of basic fibroblast growth factor incorporating gelatin microspheres on erectile function in the diabetic rat. J Urol. 2005 Apr;173 (4):1423–8. DOI: 10.1097/01. ju.0000149034.49289.2b

52. Ding XG, Li SW, Zheng XM, Hu LQ, Hu WL, Luo Y. The effect of platelet-rich plasma on cavernous nerve regeneration in a rat model. Asian J Androl. 2009 Mar;11 (2):215–21. DOI: 10.1038/aja.2008.37

53. Wu YN, Wu CC, Sheu MT, Chen KC, Ho HO, Chiang HS. Opti-mization of platelet-rich plasma and its effects on the recovery of erectile function aſter bilateral cavernous nerve injury in a rat model. J Tissue Eng Regen Med. 2016 Oct;10 ( 10):E294-E304. DOI: 10.1002/term.1806

54. ChunHou Liao, YiNo Wu, HanSun Chiang. MP43–09 Effects of platelet rich plasma on improving erectile dysfunction in streptozotocin-induced diabetic rats. The Journal of Urology. 2018;199 (4S).

55. Reinders Y, Felthaus O, Brockhoff G, Pohl F, Ahrens N, Prantl L, Haubner F. Impact of Platelet-Rich Plasma on Viability and Proliferation in Wound Healing Processes aſter External Radiation. Int J Mol Sci. 2017 Aug 22;18 (8). pii: E1819. DOI: 10.3390/ijms18081819

56. RF Patent No. 2514639 for invention «Method of treating erectile dysfunction» (Inventors : Chalyy M.E ., Vilkin Y.F. Epifanova M.V.). Moscow. Granted March 5, 2014.

57. Глыбочко П.В., Чалый М. Е., Епифанова М. В., Ахвледиан и Н.Д., Краснов А.О. Применение аутоплазмы, обогащенной тромбоцитарными факторами роста, в лечении эректильной дисфункции. Урология. 2015;1:100–3. DOI: 10.18565/urol.2017.4.46– 48

58. Епиф анова М.В., Ч алый М.Е., Краснов А.О. Исследование механизмов действия факторов роста в аутоплазме, обогащенной тромбоцитами, применяемой для лечения эректильной дисфункции. Урология. 2017;4:46–8.

59. Alkhayal S, Lourdes M. Corporeal rejuvenation with platelet rich plasma as a treatment for erectile dysfunction. Proceedings of the 21st World Meeting on Sexual Medicine. July 2018. Volume 15, Issue 7, Supplement 3, Page S254

60. Matz EL, Pearlman AM, Terlecki RP. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investig Clin Urol. 2018 Jan;59 (1):61–65. DOI: 10.4111/icu.2018.59.1.61